542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19

BACKGROUND: Bamlanivimab is a monoclonal antibody that was granted an emergency use authorization by the US Food and Drug Administration in November 2020 for patients with mild to moderate coronavirus disease 2019 (COVID-19). It initially showed promising results with decreasing hospitalizations and...

Descripción completa

Detalles Bibliográficos
Autores principales: Brock, Patricia, Dagher, Hiba, Wechsler, Adriana H, Lipe, Demis N, Chaftari, Patrick, Chaftari, Anne-Marie, Gaeta, Maria S, Johnson, Tami N, Coussirat, Daniel J, Aitken, Samuel L, Jiang, Ying, Malek, Alexandre, Hachem, Ray Y, Raad, Issam I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644538/
http://dx.doi.org/10.1093/ofid/ofab466.741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644538/
http://dx.doi.org/10.1093/ofid/ofab466.741

Ejemplares similares